胸腔热灌注联合静脉化疗治疗晚期非小细胞肺癌合并胸腔积液的临床效果  

Clinical effect of thoracic hyperthermic perfusion combined with intravenous chemotherapy in the treatment of advanced non-small cell lung cancer complicated with pleural effusion

作　　者：韩爽 王慧敏 陈旭芳 HAN Shuang;WANG Huimin;CHEN Xufang(No.1 Oncology Department,Yantai Affiliated Hospital of Binzhou Medical University,Yantai 264100,China)

机构地区：[1]滨州医学院烟台附属医院肿瘤一科,山东烟台264100

出　　处：《临床医学研究与实践》2023年第6期43-46,共4页Clinical Research and Practice

摘　　要：目的观察胸腔热灌注联合静脉化疗治疗晚期非小细胞肺癌(NSCLC)合并胸腔积液的临床效果。方法对2019年1月1日至2021年12月31日收治的102例晚期NSCLC合并胸腔积液患者的临床资料进行回顾性分析,符合纳入及排除标准的共71例,根据治疗方法将其分为观察组(32例,接受胸腔热灌注联合静脉化疗)和对照组(39例,接受胸腔注入化疗药物联合静脉化疗)。比较两组的胸腔积液控制效果、实体瘤治疗效果、生活质量、胸腔积液控制时间、生存时间及不良反应发生情况。结果观察组的胸腔积液控制率为93.8%,明显高于对照组的74.4%,差异具有统计学意义(P<0.05)。两组的实体瘤客观缓解率(ORR)、疾病控制率(DCR)比较,差异无统计学意义(P>0.05)。治疗后,观察组的卡氏功能状态(KPS)评分高于对照组,差异具有统计学意义(P<0.05)。观察组与对照组的胸腔积液中位控制时间分别为3个月和2.5个月,差异具有统计学意义(P<0.05)。观察组与对照组的中位生存时间分别为6.3个月和5.5个月,差异无统计学意义(P>0.05)。两组患者的常见不良反应为消化道反应和骨髓抑制。结论胸腔热灌注联合静脉化疗较胸腔注入化疗药物联合静脉化疗提高了NSCLC合并胸腔积液的控制率、延长了胸腔积液控制时间,提高了患者的生活质量,且其不良反应轻,耐受性好。Objective To observe the clinical effect of thoracic hyperthermic perfusion combined with intravenous chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)complicated with pleural effusion.Methods The clinical data of 102 patients with advanced NSCLC complicated with pleural effusion admitted from January1,2019 to December 31,2021 were retrospectively analyzed.A total of 71 patients who met the inclusion and exclusion criteria were divided into observation group(32 cases,received thoracic hyperthermic perfusion combined with intravenous chemotherapy)and control group(39 cases,received intrapleural infusion of chemotherapy drugs combined with intravenous chemotherapy).The pleural effusion control effect,solid tumor treatment effect,quality of life,pleural effusion control time,survival time and occurrence of adverse reactions were compared between the two groups.Results The pleural effusion control rate of the observation group was 93.8%,which was significantly higher than 74.4%of the control group,and the difference was statistically significant(P<0.05).There were no significant differences in objective response rate(ORR)and disease control rate(DCR)of solid tumor between the two groups(P>0.05).After treatment,the Karnofsky Performance Status(KPS)score of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The median control time of pleural effusion in the observation group and the control group was 3months and 2.5 months,respectively,and the difference was statistically significant(P<0.05).The median survival time of the observation group and the control group was 6.3 months and 5.5 months,respectively,and the difference was not statistically significant(P>0.05).The common adverse reactions of the two groups were gastrointestinal reaction and bone marrow suppression.Conclusion Compared with intrapleural infusion of chemotherapy drugs combined with intravenous chemotherapy,thoracic hyperthermic perfusion combined with intra

关 键 词：胸腔热灌注 静脉化疗 非小细胞肺癌 胸腔积液 

分 类 号：R730.5[医药卫生—肿瘤]